Cancer affects 1.6 million Americans in the US each year. Over 37,000 Washington State residents are diagnosed with cancer each year and it has been the overall leading cause of death since 2004. In 2012, cancer was responsible for 12,170 deaths and accounted for approximately 24% of all deaths statewide. Since 1983, the NCI has extended cancer research into the community and facilitated the translation of research into evidenced based practice through the Community Clinical Oncology Programs (CCOPs). For the past 30 years, cancer patients in the Pacific Northwest have had access to NCI funded oncology clinical trials via two large community based research networks: Northwest CCOP and Virginia Mason CCOP. These two highly experienced CCOPs share a 30 year history as separate, but adjacent CCOPs and have joined to form the Northwest NCI Community Oncology Research Program (NW NCORP). The NW NCORP recognizes the critical contributions that community cancer research programs occupy in clinical research continuum. According to the NCI about 85% of cancer patients are treated in or near their communities. Community hospitals keep patients close to family, friends, and jobs, while treatment at major Cancer Centers may require extended commutes or long stays away from home. Our service orientation and position in the cancer research design-implement-delivery continuum demands collaboration with likeminded community-based entities and modernization of our ability to connect to diverse patient populations and other stakeholders. With our fundamental principle of clinical research collaboration and cancer care delivery, the specific aims of the NW NCORP community site are: (1) Accelerate access to clinical trials in real-world healthcare delivery settings for cancer patients across the lifespan (pediatrics, adolescent and young adults, and adults); (2) Build infrastructure for the cancer care delivery research program (CCDR) in preparation for the capacity to conduct CCDR clinical trials across the NW NCORP Network; and (3) Develop active strategies for enhancing interaction with NCI-supported programs.
As a network of community hospitals, clinics, and multidisciplinary providers focused on the entire spectrum of cancer patients (pediatrics to aging adults), the NW NCORP offers a 'real-world' setting for cancer patients to access new and emerging medical treatments and supportive care via a national clinical research network.
|Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332|
|Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504|
|Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703|
|Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40|
|Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952|
|Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527|
|Stephens, Deborah M; Li, Hongli; LeBlanc, Michael L et al. (2016) Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. J Clin Oncol 34:2997-3004|
|Puvvada, Soham D; Stiff, Patrick J; Leblanc, Michael et al. (2016) Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. Br J Haematol 174:686-91|
|Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95|
|Schott, Anne F; Barlow, William E; Van Poznak, Catherine H et al. (2016) Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat 159:87-95|